|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0007222,
umls-concept:C0007820,
umls-concept:C0008359,
umls-concept:C0034656,
umls-concept:C0036043,
umls-concept:C0150097,
umls-concept:C0178602,
umls-concept:C0205171,
umls-concept:C0425358,
umls-concept:C0442027,
umls-concept:C1274040,
umls-concept:C1548795,
umls-concept:C2700615
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
1992-10-26
|
|
pubmed:abstractText |
We conducted a double-blind, placebo-controlled, randomized crossover study to evaluate the safety and immunogenicity of a single 5 x 10(8)-CFU dose of live oral recombinant cholera vaccine CVD 103-HgR in 94 North American adults. The vaccine was well tolerated without associated adverse reactions. Despite minimal fecal excretion of vaccine, 97% of subjects exhibited serum vibriocidal antibody and 72% had antitoxin responses.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/1398956-1583321,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1398956-1681168,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1398956-2087879,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1398956-2101480,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1398956-2807523,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1398956-2900401,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1398956-3335402,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1398956-3882744,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1398956-6693169,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1398956-7003031,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1398956-7050714,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1398956-7069227
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0019-9567
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
60
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4430-2
|
|
pubmed:dateRevised |
2010-9-7
|
|
pubmed:meshHeading |
pubmed-meshheading:1398956-Administration, Oral,
pubmed-meshheading:1398956-Adolescent,
pubmed-meshheading:1398956-Adult,
pubmed-meshheading:1398956-Antibodies, Bacterial,
pubmed-meshheading:1398956-Cholera Vaccines,
pubmed-meshheading:1398956-Double-Blind Method,
pubmed-meshheading:1398956-Female,
pubmed-meshheading:1398956-Humans,
pubmed-meshheading:1398956-Male,
pubmed-meshheading:1398956-Safety,
pubmed-meshheading:1398956-Vaccines, Synthetic
|
|
pubmed:year |
1992
|
|
pubmed:articleTitle |
Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: results of a randomized, placebo-controlled, double-blind crossover trial.
|
|
pubmed:affiliation |
Department of Pediatrics, University of Maryland School of Medicine, Baltimore 21201.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
